https://doi.org/10.4081/hmr.v2i5.760

New agents for the treatment of acute myeloid leukemia: midostaurin

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 214
PDF: 874
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

S Amadori
support@pagepress.org
FLT3, a membrane-bound receptor tyrosine kinase (TK) expressed by immature hematopoietic cells, plays an important role in an early stage of hematopoiesis.1 FLT3 is among the most commonly mutated genes in acute myeloid leukemia (AML). Approximately 30% of AML patients have mutations of FLT3 that result in constitutive phosphorylation and activation of FLT3, and subsequent activation of downstream signal molecules important for cellular proliferation, differentiation, and survival.2 These mutations typically result in either an internal tandem duplication (ITD) of between 3 and 33 or more amino acids in the juxtamembrane region of the FLT3 protein (25% of patients), or a less common (5-10%) point mutation in the activation loop of the thyrosine kinase domaine (TKD).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Amadori, S. (2009). New agents for the treatment of acute myeloid leukemia: midostaurin. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.760
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).